Thank you, Mr. Chair, for indulging me as an associate member of this committee.
My normal role, besides sitting with Mr. Hanley on fisheries, is as vice-chair of the industry committee. I've had a motion for a study on Medicago on the industry committee since the spring, but legislation takes precedence. We were dealing with Bill C-34 on the Investment Canada Act changes and Bill C-27, the privacy and artificial intelligence bill, so we've not had a chance to get to the motion.
That is why I think the motion here before the committee is so important. The industry committee did an examination, initially—it was tabled in June, since it was started in the last Parliament—of the response to COVID-19 in terms of vaccines, as, I believe, this committee did. I believe there are not only minister of health issues with regard to this study but also a large industry role. Unfortunately, the industry committee doesn't have time to discuss it.
You will note, in the appendix of the report tabled in the House on June 14 by the industry committee, that an agreement with Medicago was signed on October 23, 2020, to purchase up to 76 million doses of the vaccine. This is a vaccine Health Canada had approved and to which the government initially committed. It was up to $223 million through a couple of funds, in order to develop a non-mRNA vaccine, a plant-based vaccine, which they successfully did. I think it got Health Canada approval.
The committee needs to study it for various reasons. It's not clear to us why not a single vaccine was produced, and why that contract was signed for 76 million. A great deal of provincial and federal government money went into creating that vaccine plant in Quebec City 10 years or so ago, in order to produce vaccines. My understanding, from everything I've seen, read and heard, is that, in this case, it was a successful vaccine with a fairly high efficacy rate.
This investment was made and seems to have not gone anywhere, mainly because the World Health Organization has a policy not to endorse products produced by companies that have any kind of tobacco manufacturing involvement. I think Philip Morris had 40% ownership, with Mitsubishi having the remainder. I'd love to ask both the health minister and the industry minister this: Why would you sign such a contract or even invest up to $223 million of taxpayer money to develop a vaccine with a company that you knew the WHO would not endorse for promotion around the world? This would leave it, essentially, a Canadian domestic market vaccine. I think there are a lot of questions to ask around that and the thinking leading up to it.
We know the thinking was about trying to develop, as MP Thériault said, domestic vaccine manufacturing capacity. A lot of money was going into it, at a very intense time in the world and in this country. In choosing to make it with this particular company, it looked to me like it was doomed to failure regarding its ability to, even if successful, be a vaccine acquired by other countries. That would ultimately be the goal in addition to our own use. Without a WHO “good housekeeping” seal of approval, it was unlikely to have any success in its sales.
In business, we call it a “sunk cost”; once it's done, you can't get it back. In this case, the sunk cost is in, so let's buy some of the vaccines and contract with it.
An incredible amount of taxpayer money went into this. Where are the patents? Who owns the patents? Where have they gone?
The inability of this organization, for whatever reason, to produce the vaccines in this plant that was set up, where 400 people worked, looked like it had a ray of light in December last year, when Mitsubishi bought out Philip Morris.
When that happened, I thought, okay, this is good news. Maybe this great taxpayer-funded vaccine can be produced and marketed around the world, now that it no longer has a tobacco company ownership structure. There are rumours out there of what Mitsubishi paid for that. Some have said it's as low as about $14 million, which is incredible, given that it had almost $200 million of federal taxpayer money with patents on a successful vaccine.
Nonetheless, we all lead a public, elected life. We're all optimists by nature, or we wouldn't be doing this job. I think we held out hope that somehow, it would be seen as a step forward.
Lo and behold, what happened six weeks later? Six weeks later, Mitsubishi shut the company down, threw 400 people in Quebec out of work—after all of that taxpayer money—and then started this dance of the questions that we started to ask.
What's happened? There's a contract to produce up to 76 million vaccines. I believe the cost was $20 per vaccine, so what are we on the hook for as a country, to pay for a vaccine that was never produced? Where did all that investment in that IP go?
I suspect we don't know the answers to that or whether or not Mitsubishi has chosen to actually sell the Canadian-financed patents for a plant-based COVID vaccine somewhere in the world. We don't know that. We haven't had it before this committee and we haven't had it before the industry committee. This committee has the opportunity, perhaps, with its agenda to do that, which we don't in the industry committee. I would be urging members to take a look at that, because it seems to me there are at least two flaws in this process.
The first flaw is that there wasn't any protection of Canadian taxpayers when $200 million was committed in a contract to develop the vaccine in the first place. There were no issues around the taxpayers' claim on the patents if something went south.
Somehow, as the financier of this, either through university-owned patents or through the rights of the granting councils through the SIF program—or whichever ISED program paid for this, because I believe the money came out of ISED—we were obviously so poor at negotiating contracts that we didn't get an ownership stake in that or any protection for the taxpayer if, for example.... They must have known going in that it would have had trouble being marketed because of the Philip Morris ownership. There wasn't some protection for the taxpayer from that company in the contract to give us the money back from Philip Morris and Mitsubishi for the investment or, in the case of the situation that arose, the fact that the taxpayer would actually own the patents so that they couldn't leave this country and couldn't be sold by a foreign multinational. However, it appears that's the situation we're in.
If that wasn't bad enough, obviously, the cancellation clauses were non-existent in the contract to buy the 76 million doses of the vaccine that were never produced, because we are now on the hook for another $150 million for something that was never made. It's thin air, it's vapour, it's nothing. It's $150 million for not even an empty vial.
There was $200 million that went into developing the vaccine and $150 million for absolutely nothing. Some 400 people in Quebec City are out of work, and Mitsubishi gets to walk away with all of the patents and all of the potential to sell them for the small price of a few million dollars buying out Philip Morris.
That's the way it appears. Maybe that's not the case. Maybe the witnesses could actually shed some light on these contracts. Maybe officials could explain to us why they signed contracts that appear to leave the Canadian taxpayer with nothing but the bill and leave a Japanese company with an innovative Canadian patented technology.
Again, because we don't have the ability to do this in Industry, we would like to get this committee to examine these things. That's why Dr. Ellis put forward the motion in the first place. I would urge that our committee members not only vote on the amendment as amended. I think that we need not limit ourselves to four meetings or six meetings. I think you have to follow the evidence and then get to the main motion so that the committee gets this on the agenda.
That's my opening. I'll leave it at that for members to consider. The numbers add up to quite a large loss to the Canadian taxpayer. To me, it's a bit of a scandal. I hope it's not. I hope we can actually get those patents back.
Thank you, Mr. Chair.